
Opinion|Videos|December 22, 2023
Updates in Lower-Risk MDS: Imetelstat
Author(s)Yazan Madanat, MD
Yazan Madanat, MD, comments on the updates that were recently presented at ASH 2023 for the management of lower-risk MDS and discusses the impact of emerging therapies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Dr Hans Lee on the Game-Changing Myeloma Research From ASH 2025
3
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
4
The Targeted Pulse: Blood and Breast Cancer News
5














































